Alkermes is a biopharmaceutical company. Co.'s products include: ARISTADA, which is an extended-release injectable suspension for the treatment of schizophrenia; VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence; INVEGA SUSTENNA/XEPLION, and RISPERDAL CONSTA, which is for the treatment of schizophrenia and for the treatment of schizoaffective disorder; AMPYRA/FAMPYRA, which is a treatment to improve walking in adults with multiple sclerosis; and BYDUREON is for the treatment of type 2 diabetes. Co.'s product candidate include Aripiprazole Lauroxil Two-Month Dose for the treatment of schizophrenia, among others.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.